Home＞BUSINESS
Shionogi, UMN Pharma Conclude Capital Alliance; Tie Up in Infectious Disease Field(Nov.2.2017)
Shionogi and the biotech startup UMN Pharma on October 31 announced a capital investment and business alliance agreement. Under the agreement, UMN Pharma will allocate 600,000 shares of common stock and a first issuance of convertible bonds with stock acquisition rights to Shionogi, which is expected to invest around 1.6 billion yen for the acquisition ...
(LOG IN FOR FULL STORY)
-
- J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use Jul.20
- Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF Jul.20
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda Jul.20
- Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug Jul.20
- Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard Jul.20
- J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use(Jul.20)
- Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF(Jul.20)
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda(Jul.20)
- Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug(Jul.20)
- Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard(Jul.20)
